A Brazilian drugmaker filed to launch its own version of the blockbuster weight-loss and diabetes drug, taking aim at a market worth billions a year.
Key Facts
—The move. Brazil’s Hypera filed to launch Semavy, its own semaglutide pen.
—The rival. It targets the same drug class as Novo Nordisk’s Ozempic.
—The market. Semaglutide moves at least R$5bn ($960m) a year in Brazil.
—The trigger. Semaglutide’s Brazilian patent expired in March 2026.
‘Ozempic nacional’: próxima caneta de semaglutida brasileira será chamada Semavy; conheça
South African court blocks pharmacy accused of selling unapproved Ozempic-style weight-loss drugs
Nova caneta de semaglutida sintética produzida no Brasil é a Semavy, da Hypera Pharma
Novo Nordisk wins interim order barring SA rival from selling Ozempic copies
Ozivy, da EMS, usa o mesmo princípio ativo do Ozempic e do Wegovy e é o primeiro medicamento baseado em semaglutida a obter…
Last week’s expiry of the patent for semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozmepic…
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
El nuevo fármaco con semaglutida llegará al mercado brasileño en las próximas semanas tras vencer la patente del medicamento…
BRAZIL · ECONOMY Key Facts —The approval: Brazil's health regulator cleared Ozivy, the country's first home-grown version of…
El medicamento se comercializará bajo el nombre Ozivy y llegará al mercado brasileño “en unas pocas semanas”.
